iptacopan – Medxy AI

Iptacopan: A Comprehensive Clinical Review of the First-in-Class Oral Factor B Inhibitor for PNH and Complement-Mediated Nephropathies

By MedXY 01/19/2026

This review synthesizes clinical trial evidence for Iptacopan, focusing on its transformative role in treating PNH through proximal complement inhibition and its emerging efficacy in IgA nephropathy and C3 glomerulopathy.

Hematology-Oncology Internal Medicine news

Iptacopan Demonstrates Clinical Efficacy in Cold Agglutinin Disease While Falling Short in Immune Thrombocytopenia: Results from a Phase 2 Basket Trial

By MedXY 01/19/2026

This Phase 2 basket trial highlights the divergent efficacy of the oral factor B inhibitor iptacopan, showing significant hemoglobin improvements in Cold Agglutinin Disease but failing to meet platelet response endpoints in Immune Thrombocytopenia.

Allergy & Immunology Nephrology

Oral Iptacopan Shows Promise in Reducing Proteinuria in C3 Glomerulopathy: Results from a Global Phase 3 Trial

By MedXY 10/10/2025

The APPEAR-C3G phase 3 trial demonstrates that oral iptacopan significantly reduces proteinuria and is well tolerated in adults with C3 glomerulopathy, an ultra-rare glomerulonephritis linked to alternative complement pathway overactivation.

Clinical Updates Internal Medicine news Pediatrics Specialties

Oral Iptacopan Monotherapy in Paroxysmal Nocturnal Haemoglobinuria: 48-Week Outcomes from APPLY-PNH and APPOINT-PNH Phase 3 Trials

By MedXY 08/03/2025

Oral iptacopan provides sustained haemolysis control and improved haemoglobin in PNH patients over 48 weeks, with a favorable safety profile, supporting its role as a new therapeutic option.